Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Overall, we achieved more than $19 million in revenue in 2023, our 11th consecutive year of revenue growth |
| So that's why we think it's a good opportunity for them |
| It's been a long journey to reach this point where we can serve patients with arm paralysis who are covered by Medicare Part B health insurance, and we're delighted that we've arrived |
| We're thrilled to be in a position both to grow the company significantly and to improve the quality of life for a larger number of patients |
| You've been able to track well-regarded fundamental healthcare investors who see the long-term potential of this business |
| And with the Medicare Part B patients now eligible for MyoPro, we had a record 183 authorizations and orders in the fourth quarter, up 87% percent from the same period a year ago |
| While we start this year in the strongest position in the company's history |
| Assuming we can increase capacity as planned, and assuming there's no unexpected supply chain disruptions, we believe we can achieve full year 2024 revenue of between $28 million to $30 million, an increase of 46% to 56% compared to the full year 2023 |
| Obviously, this is great news with the reimbursement coming in at the levels that it came in at and the backlog and pipeline growing |
| I met with some of them last week and we're getting good reimbursement progress there in Germany |
| We're delighted to put this major reimbursement issue behind us and 2024 will be a transformational year for Myomo |
| This growth was driven by a higher number of revenue units, which were up 6% over the 2022 fourth quarter, and a higher average selling price, or ASP |
| Gross margin expansion should be resumed year-over-year during the second half of 2024 |
| Can you talk a little bit about how those folks look at the product and maybe a little bit more color on the sorts of people you're meeting with at the upcoming conference here, Paul, for the O&P folks? Paul Gudonis Well, the O&P channel is very well positioned to provide the MyoPro to patients, what's been a barrier to adoption has been the reimbursement process and that's why we integrated forward with our own direct billing clinical team in the field |
| So that's where we get some really good efficiencies because we've already built the infrastructure for the company |
| These additional Part B patients added to the backlog contributed to a record 183 authorizations, orders, and other additions to the backlog in the fourth quarter, which was up 87% over the prior year quarter |
| We have a growing possible business in Germany, and we should see continuing growth in international revenues as more O&P clinics become trained on how to provision MyoPro, and a larger number of the German’s cash for health insurers cover the device for their beneficiaries |
| As a result, we estimate first quarter 2024 revenues will be in the range of $4.1 million to $4.3 million, an increase of between 19% and 25%, compared with the year ago quarter, with growth accelerating through the remainder of 2024 |
| We built up a really good business development a clinical team now |
| We delivered over 400 MyoPros to patients in the U.S., Germany, and several other international markets last year, and we became more efficient with our marketing, reducing the cost for pipeline adds while operating with fewer staff members |
| And finally, because of this Medicare Part B coverage now in place, we are seeing new interest among orthotics and prosthetics clinics around the country in supplying the MyoPro to their patients with a much clearer reimbursement path this O&P channel can develop into a significant source of product sales in the future |
| Overall, we grew our pipeline to more than 1, 000 patients by the end of the year and our backlog, which includes Medicare Part B patients awaiting delivery of their device, due to 230 units, which is up 40% from the end of 2022 |
| Thanks for your continued interest in our company and have a good day |
| Our backlog at the end of quarter 2023 was a record 230 patients, which was up 40% from our backlog at the end of the fourth quarter of 2022 |
| A year ago, we met with the DME MAC’s medical directors and shared our research about the valuable outcomes that were achieved by Medicare H beneficiaries, and we were encouraged to deliver MyoPros to this population and then submit claims |
| Our investment in the high-quality clinical research resulted in Medicare coverage of our powered arm braces, and this milestone has a number of benefits |
| Our international team will continue to grow |
| To summarize our full year results, revenue for 2023 was $19.2 million, up 24% compared to 2022, while 2023 product revenue of $17.5 million was up 20% |
| So we'll continue to see growth in our Medicare Advantage, commercial plans |
| We're now focused on scaling the business with operational efficiencies so that we can meet this increased demand, achieve our goals of cash flow breakeven by the end of the year under the various assumptions that Dave pointed out |
| Statement |
|---|
| Adjusted EBITDA for the fourth quarter of 2023 was a negative $2.1 million compared with the negative $1.9 million for the fourth quarter of 2022 |
| We expect some gross margin pressure in the first half of 2024 as we grant deliveries to Medicare patients, recording costs of goods sold at that time, while recording revenue and payments, until we build sufficient collection history to enable recording revenue delivery |
| Adjusted EBITDA was a negative $7 million for 2023 compared with a negative $9.3 million for 2022 |
| Net loss for the fourth quarter of 2023 was $2.5 million, or $0.07 per share |
| We took down our headcount by 12% early in the year and reduced our advertising expenses by nearly $1 million, and yet we still drew our product revenues by 20% year-over-year, we added license revenue from our China joint venture, and we cut our cash use and operations by nearly 40% down to $6.2 million for the year from over $10 million in the year before |
| The operating loss for the fourth quarter of 2023 was $2.4 million, compared with an operating loss of $2.2 million for the fourth quarter of 2022 |
| This compares to the net loss of $2.2 million, or $0.29 per share for the fourth quarter of 2022 |
| Some of the Medicare Advantage plans have publicly stated that they are seeing increased medical costs post-COVID as patients seek treatments, they may have postponed, and we've seen a short-term impact out authorizations received in the last few months from these payers and what may be an attempt to manage utilization |
| Our cost for pipeline add was $2, 246 which is down 16% compared with the prior year quarter |
| So at that time, we decided to focus on reliable payers, such as certain Medicare Advantage plans, and reduce our cash burn during the year while waiting for these decisions |
| These individuals, their families, and their clinicians are already contacting us, so our cost per pipeline add should come down over time |
Please consider a small donation if you think this website provides you with relevant information